Overview Dividends

(NBIX) Neurocrine Biosciences - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US64125C1099

Movement, Endocrine, Neuropsychiatric, Gynecology, Pediatric

NBIX EPS (Earnings per Share)

EPS Growth (3Y CAGR): 38.85%
EPS Trend (3Y Correlation): 59.0%

NBIX Revenue

Revenue Growth (3Y CAGR): 27.00%
Revenue Trend (3Y Correlation): 95.9%

Risk via 10d forecast
Volatility	32.8%
Value at Risk 5%th	45.9%

Reward
Sharpe Ratio	0.59
Alpha	12.88

Character
Hurst Exponent	0.324
Beta	0.212

Drawdowns 3y
Max DD	42.89%
Mean DD	13.62%

Description: NBIX Neurocrine Biosciences October 30, 2025

Neurocrine Biosciences (NASDAQ: NBIX) is a San-Diego-based biotech that discovers, develops, and commercializes medicines for neurological, neuroendocrine, and neuropsychiatric diseases, primarily in the United States but with growing international reach.

Its commercial portfolio includes INGREZZA (valbenazine) for tardive dyskinesia and Huntington’s chorea, ALKINDI for adrenal insufficiency, Efmody for classic congenital adrenal hyperplasia, Orilissa for endometriosis, Oriahnn for uterine fibroids, and CRENESSITY for congenital adrenal hyperplasia. The pipeline features valbenazine extensions (e.g., dyskinetic cerebral palsy, schizophrenia), NBI-1076986 for movement disorders, Osavampator and NBI-1070770 for major depressive disorder, and multiple NBI-1117xxx candidates targeting schizophrenia and other neuropsychiatric conditions.

In FY 2024 NBIX generated ≈ $1.3 billion in revenue, with INGREZZA contributing roughly $480 million-demonstrating the commercial traction of its core valbenazine franchise. R&D spending remained above $300 million, reflecting a sector-wide trend where biotech firms reinvest > 20 % of sales into pipeline expansion to offset the high attrition rate of CNS programs. The global market for neuroendocrine disorders is projected to grow at a CAGR of ~ 6 % through 2030, providing a macro-level tailwind for NBIX’s specialty focus.

For a deeper, data-driven view of NBIX’s valuation dynamics and how its pipeline risk-reward profile stacks up against peers, you may find the analytical tools on ValueRay worth a quick look.

NBIX Stock Overview

Market Cap in USD	14,279m
Sub-Industry	Biotechnology
IPO / Inception	1996-05-23
Return 12m vs S&P 500	2.41%
Analyst Rating	4.48 of 5

NBIX Dividends

Currently no dividends paid

NBIX Growth Ratios

CAGR	8.40%
CAGR/Max DD Calmar Ratio	0.20
CAGR/Mean DD Pain Ratio	0.62
Current Volume	964.3k
Average Volume	798.4k

Piotroski VR‑10 (Strict, 0-10) 6.5

Net Income (428.0m TTM) > 0 and > 6% of Revenue (6% = 161.0m TTM)

FCFTA 0.14 (>2.0%) and ΔFCFTA 1.45pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 56.67% (prev 64.51%; Δ -7.84pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.15 (>3.0%) and CFO 636.8m > Net Income 428.0m (YES >=105%, WARN >=100%)

Net Debt (88.2m) to EBITDA (665.4m) ratio: 0.13 <= 3.0 (WARN <= 3.5)

Current Ratio 3.38 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (102.5m) change vs 12m ago -1.73% (target <= -2.0% for YES)

Gross Margin 98.37% (prev 98.52%; Δ -0.15pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 68.78% (prev 63.45%; Δ 5.34pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 5.02 (EBITDA TTM 665.4m / Interest Expense TTM 126.6m) >= 6 (WARN >= 3)

Altman Z'' 3.91

(A) 0.36 = (Total Current Assets 2.16b - Total Current Liabilities 638.0m) / Total Assets 4.27b

(B) 0.07 = Retained Earnings (Balance) 294.0m / Total Assets 4.27b

(D) 0.24 = Book Value of Equity 307.3m / Total Liabilities 1.26b

Total Rating: 3.91 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 88.15

1. Piotroski 6.50pt = 1.50

2. FCF Yield 4.36% = 2.18

3. FCF Margin 22.11% = 5.53

4. Debt/Equity 0.14 = 2.49

5. Debt/Ebitda 0.13 = 2.49

6. ROIC - WACC (= 10.29)% = 12.50

7. RoE 15.82% = 1.32

8. Rev. Trend 95.91% = 7.19

9. EPS Trend 59.04% = 2.95

What is the price of NBIX shares?

As of November 11, 2025, the stock is trading at USD 150.02 with a total of 964,285 shares traded.
Over the past week, the price has changed by +5.68%, over one month by +9.80%, over three months by +21.00% and over the past year by +17.97%.

Is Neurocrine Biosciences a good stock to buy?

Yes, based on ValueRay´s Fundamental Analyses, Neurocrine Biosciences (NASDAQ:NBIX) is currently (November 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 88.15 and therefor a positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of NBIX is around 144.70 USD . This means that NBIX is currently overvalued and has a potential downside of -3.55%.

Is NBIX a buy, sell or hold?

Neurocrine Biosciences has received a consensus analysts rating of 4.48. Therefore, it is recommended to buy NBIX.

Strong Buy: 15
Buy: 7
Hold: 3
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the NBIX price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	174.5	16.3%
Analysts Target Price	174.5	16.3%
ValueRay Target Price	159.5	6.3%

NBIX Fundamental Data Overview November 02, 2025

Market Cap USD = 14.28b (14.28b USD * 1.0 USD.USD)
P/E Trailing = 34.0976
P/E Forward = 25.7732
P/S = 5.3226
P/B = 5.0336
P/EG = 0.2733
Beta = 0.212
Revenue TTM = 2.68b USD
EBIT TTM = 635.7m USD
EBITDA TTM = 665.4m USD
Long Term Debt = 455.1m USD (from capitalLeaseObligations, last fiscal year)
Short Term Debt = unknown (none)
Debt = 428.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 88.2m USD (from netDebt column, last quarter)
Enterprise Value = 13.59b USD (14.28b + Debt 428.4m - CCE 1.11b)
Interest Coverage Ratio = 5.02 (Ebit TTM 635.7m / Interest Expense TTM 126.6m)
FCF Yield = 4.36% (FCF TTM 593.1m / Enterprise Value 13.59b)
FCF Margin = 22.11% (FCF TTM 593.1m / Revenue TTM 2.68b)
Net Margin = 15.95% (Net Income TTM 428.0m / Revenue TTM 2.68b)
Gross Margin = 98.37% ((Revenue TTM 2.68b - Cost of Revenue TTM 43.8m) / Revenue TTM)
Gross Margin QoQ = 98.24% (prev 98.36%)
Tobins Q-Ratio = 3.19 (Enterprise Value 13.59b / Total Assets 4.27b)
Interest Expense / Debt = 29.55% (Interest Expense 126.6m / Debt 428.4m)
Taxrate = 28.20% (82.3m / 291.8m)
NOPAT = 456.4m (EBIT 635.7m * (1 - 28.20%))
Current Ratio = 3.38 (Total Current Assets 2.16b / Total Current Liabilities 638.0m)
Debt / Equity = 0.14 (Debt 428.4m / totalStockholderEquity, last quarter 3.00b)
Debt / EBITDA = 0.13 (Net Debt 88.2m / EBITDA 665.4m)
Debt / FCF = 0.15 (Net Debt 88.2m / FCF TTM 593.1m)
Total Stockholder Equity = 2.71b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.03% (Net Income 428.0m / Total Assets 4.27b)
RoE = 15.82% (Net Income TTM 428.0m / Total Stockholder Equity 2.71b)
RoCE = 20.11% (EBIT 635.7m / Capital Employed (Equity 2.71b + L.T.Debt 455.1m))
RoIC = 17.51% (NOPAT 456.4m / Invested Capital 2.61b)
WACC = 7.22% (E(14.28b)/V(14.71b) * Re(6.80%) + D(428.4m)/V(14.71b) * Rd(29.55%) * (1-Tc(0.28)))
Discount Rate = 6.80% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 33.33 | Cagr: 0.10%
[DCF Debug] Terminal Value 81.43% ; FCFE base≈531.9m ; Y1≈656.2m ; Y5≈1.12b
Fair Price DCF = 191.0 (DCF Value 19.04b / Shares Outstanding 99.7m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 59.04 | EPS CAGR: 38.85% | SUE: 0.27 | # QB: 0
Revenue Correlation: 95.91 | Revenue CAGR: 27.00% | SUE: 2.77 | # QB: 2

Additional Sources for NBIX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle